Q-Line Biotec IPO is a 100% fresh issue book-built SME offering valued at ₹214.48 crores. The issue consists entirely of 62,53,200 equity shares with a face value of ₹10 each. The official price band is set between ₹326 and ₹343 per share. Retail investors can participate with a minimum lot size of 400 shares, translating to an investment of ₹1,37,200 at the lower band and ₹2,74,400 for the maximum 2-lot retail cap at the upper band. High Net Worth Investors (S-HNI) require a minimum bidding threshold of 3 lots (1,200 shares) amounting to ₹4,11,600. The shares are scheduled to be formally listed on the NSE SME platform.
Q-Line Biotech IPO Objectives
The objectives of the fund issue are discussed below:
- ₹93.50 crore will be used to meet the company’s growing working capital requirements.
- ₹90 crore has been earmarked for repayment or pre-payment of certain existing borrowings, either partially or fully.
- The remaining amount will be utilised for general corporate purposes and business expansion needs.
About Q-Line Biotech
Founded in 2010, Q-Line Biotech Ltd. operates in the healthcare diagnostics space with a focus on developing, manufacturing, and marketing diagnostic reagents, consumables, and Point-of-Care (POC) devices. The company also imports, manufactures, and distributes advanced Pathology and In-Vitro Diagnostic (IVD) equipment to hospitals, medical colleges, and diagnostic laboratories across India.
Over the years, Q-Line Biotech has built a presence across multiple diagnostic segments, including Hematology, Clinical Chemistry, and Rapid/ELISA testing solutions. As of December 31, 2025, the company had an annual manufacturing capacity of nearly 1.4 million testing kits along with around 1,200 Selectra testing machines.
Its operations are supported by a workforce of 126 permanent employees and 223 specialised third-party professionals working across areas such as research and development, manufacturing, and supply chain management. The company continues to focus on expanding its product portfolio while strengthening its distribution and operational capabilities in India’s growing diagnostics market.
Industry Outlook
- The Indian In-Vitro Diagnostics (IVD) market is projected to expand steadily at a CAGR of over 6% between 2026 and 2031, crossing a market valuation of $2.66 billion by 2031.
- Rising incidences of chronic conditions like diabetes (affecting over 101 million citizens) and cardiovascular diseases alongside recurrent communicable infections are massively driving test volumes.
- The Point-of-Care (POC) diagnostic platforms and rapid test kits are witnessing hyper-growth, expanding at a CAGR of 14.93% due to immediate turnaround time demands.
- Reagents and consumables hold the largest share of the product pie, capturing over 64.78% of the entire IVD market size due to recurring recurring-revenue model needs.
- Tier-2 and Tier-3 urban/semi-urban belts are developing into primary revenue growth engines through hub-and-spoke laboratory distribution models.
- High-throughput automation, AI integration, and digital workflow ecosystem platforms are replacing traditional manual pathology procedures to bridge staffing capacity deficits.
How To Apply for the Q-Line Biotech IPO Online?
- Login to Your Angel One Account: Open the Angel One app or website and log in with your credentials.
- Locate the IPO Section: Navigate to the 'IPO' section on the platform.
- Select IPO: Find and select the Q-Line Biotech IPO from the list of open IPOs.
- Enter the Lot Size: Specify the number of lots you want to bid for.
- Submit Your UPI ID: Enter your UPI ID to link your payment method and submit your application.
- Approve Funds: Once you receive the bid request on your UPI app, approve it by entering your UPI PIN.
How To Check the Allotment Status of Q-Line Biotech IPO?
Steps to check IPO allotment status on Angel One’s app:
- Log in to the Angel One app.
- Go to the IPO Section and then to IPO Orders.
- Select the individual IPO that you had applied for and check the allotment status.
- Angel One will notify you of your IPO allotment status via push notification and email.
Contact Details of Q-Line Biotech
Registered Office Address: 298-281, Transport Nagar, Kanpur Road, Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh - 226012, India.
Telephone Contact: +91 522-2435570
Official Email ID: compliance@qlinebiotech.com
Q-Line Biotech IPO Reservation
| Investor Category | % of Total Issue |
| Market Maker (Hem Finlease) | 5.01% |
| QIB Shares Offered | 47.48% |
| Anchor Portion Allocation | 28.48% |
| Net QIB (Ex-Anchor) | 19.00% |
| NII (HNI) Shares Offered | 14.26% |
| Retail Shares Offered (RII) | 33.25% |
| Total Allocation | 100.00% |
Q-Line Biotech IPO Lot Size Details
| Application Category | Lots | Shares | Amount |
| Individual Investors (Retail) – Min | 2 | 800 | ₹2,74,400 |
| Individual Investors (Retail) – Max | 2 | 800 | ₹2,74,400 |
| S-HNI – Min | 3 | 1,200 | ₹4,11,600 |
| S-HNI – Max | 7 | 2,800 | ₹9,60,400 |
| B-HNI – Min | 8 | 3,200 | ₹10,97,600 |
Q-Line Biotech IPO Promoter Holding
The promoters of the company include Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal.
| Share Holding Pre-Issue | 96.77% |
| Share Holding Post Issue | NA |
Note: Equity dilution will be determined by subtracting the Shareholding Post Issue from the Shareholding Pre Issue.
Key Performance Indicators for Q-Line Biotech IPO
| Key Performance Indicator | Value (%) / Ratio |
| Return on Equity (ROE) | 16.88% |
| Return on Capital Employed (ROCE) | 13.32% |
| Return on Net Worth (RoNW) | 16.88% |
| PAT Margin | 16.65% |
| EBITDA Margin | 27.64% |
| Debt to Equity Ratio | 1.06 |
Q-Line Biotech IPO Registrar and Lead Managers
Q-Line Biotech IPO Lead Managers
- Lead Manager 1: Hem Securities Ltd.
Address: 904, 9th Floor, K处理 Building, Outer Circle, Connaught Place, New Delhi - 110001. (Also offices in Mumbai/Jaipur).
- Lead Manager 2: Share India Capital Services Pvt. Ltd.
Address: A-15, Sector-64, Noida, Uttar Pradesh - 201301.
Registrar for Q-Line Biotech IPO
Name: Purva Sharegistry (India) Pvt. Ltd.
Address: Unit no. 9, Shiv Shakti Ind. Estt., J.R. Boricha Marg, Opp. Kasturba Hospital Lane, Lower Parel (E), Mumbai - 400011, Maharashtra.
Phone: +91-022-23018261 / 23016761
Email: support@purvashare.com
Financial Performance of Q-Line Biotech IPO
| Key Metrics | Period Ended 31-Dec-2025 | FY 2024-25 (31-Mar-2025) | FY 2023-24 (31-Mar-2024) | FY 2022-23 (31-Mar-2023) |
| Total Assets | ₹561.34 | ₹455.49 | ₹339.25 | ₹251.58 |
| Total Income | ₹236.50 | ₹322.58 | ₹206.45 | ₹184.81 |
| EBITDA | ₹64.23 | ₹71.32 | ₹37.63 | ₹32.98 |
| Profit After Tax (PAT) | ₹38.69 | ₹28.13 | ₹34.44 | ₹32.10 |
| Total Borrowings | ₹243.85 | ₹164.95 | ₹96.91 | ₹73.65 |
Note: All figures are in ₹ Crore.
Q-Line Biotech Peer Comparison
According to the company’s Red Herring Prospectus (RHP), Q-Line Biotech Ltd. does not have any directly comparable listed peers in the Indian market. The company operates in a niche segment that combines indigenous reagent manufacturing with the import and distribution of specialised IVD medical equipment.
As a result, the IPO valuation is largely being assessed based on the company’s own financial performance, business growth, and operational strengths rather than direct peer comparisons.
Strengths and Opportunities of Q-Line Biotech
- The company has built a strong presence across multiple segments of the IVD industry, including Clinical Chemistry, Hematology, Molecular Diagnostics, and Point-of-Care devices.
- It has developed a proven indigenous manufacturing setup with the capacity to produce nearly 1.4 million diagnostic kits annually as of late 2025.
- A dedicated research and development focus, supported by reverse engineering expertise, helps the company customize products and optimize manufacturing costs efficiently.
- The company has established a well-integrated supply chain and distribution framework with customer reach across all four major regions of India.
- Long-standing sourcing and assembly relationships support the supply of proprietary systems, including Selectra diagnostic platforms.
- Since 2013, the company has maintained long-term relationships with leading diagnostic chains, hospitals, and medical universities across India.
- The business is led by experienced promoters from the Garg family and associates, backed by strong technical and operational expertise in the diagnostics sector.
Risks and Threats of Q-Line Biotech
- Based on restated financial parameters, the upper price band of ₹343 per share reflects aggressive pricing valuations.
- A noticeable dip in net profitability occurred during FY25 (PAT fell to ₹28.13 crore from ₹34.44 crore in FY24) due to internal accounting adjustments.
- Total borrowings scaled up sharply from ₹73.65 crore in FY23 to ₹243.85 crore by late December 2025.
- Operational models require heavy cash allocations, requiring ₹93.50 crores of IPO funding to balance inventory cycles.
- SME platform listings generally carry higher liquidity risks compared to mainboard equity options post-listing.
- Diagnostic kit manufacturing is heavily scrutinized by Central Drugs Standard Control Organization (CDSCO) mandates; any compliance lapse could stop production.
- Facing severe price undercutting pressures from global medical giants (Roche, Abbott) and domestic medical device aggregators.
